E-LIB Suche - Ergebnisse für: Dangond, Fernando

1

Twenty Years of Subcutaneous Interferon-Beta-1a for Multipl..:

Freedman, Mark S. ; Coyle, Patricia K. ; Hellwig, Kerstin...
Neurology and Therapy. 13 (2024) 2 - p. 283-322 , 2024

Link: https://doi.org/10.1007/..

2

Side Effects That Occurred Early in People With Multiple Sc..:

Oh, Jiwon ; Walker, Bryan ; Giovannoni, Gavin...
Neurodegenerative Disease Management. 12 (2022) 1 - p. 1-7 , 2022

Link: https://doi.org/10.2217/..

3

Disease Stability Over Five Years in People With Multiple S..:

Giovannoni, Gavin ; Comi, Giancarlo ; Rammohan, Kottil...
Neurodegenerative Disease Management. 12 (2022) 6 - p. 295-301 , 2022

Link: https://doi.org/10.2217/..

4

The Effect of Cladribine Tablets in People With More Active..:

Vermersch, Patrick ; Galazka, Andrew ; Dangond, Fernando...
Neurodegenerative Disease Management. 12 (2022) 6 - p. 285-293 , 2022

Link: https://doi.org/10.2217/..

5

Relapses in People With Multiple Sclerosis Treated With Cla..:

Stefano, Nicola De ; Sormani, Maria Pia ; Giovannoni, Gavin...
Neurodegenerative Disease Management. 12 (2022) 6 - p. 303-310 , 2022

Link: https://doi.org/10.2217/..

6

Determination of a clinically effective evobrutinib dose: E..:

Papasouliotis, Orestis ; Mitchell, David ; Girard, Pascal..
Clinical and Translational Science. 15 (2022) 12 - p. 2888-2898 , 2022

Link: https://doi.org/10.1111/..

7

Long-Term Disease Stability Assessed by the Expanded Disabi..:

Giovannoni, Gavin ; Comi, Giancarlo ; Rammohan, Kottil...
Advances in Therapy. 38 (2021) 9 - p. 4975-4985 , 2021

Link: https://doi.org/10.1007/..

8

Efficacy of cladribine tablets in high disease activity pat..:

Vermersch, Patrick ; Galazka, Andrew ; Dangond, Fernando...
Current Medical Research and Opinion. 37 (2021) 3 - p. 459-464 , 2021

Link: https://doi.org/10.1080/..

9

Facing the urgency of therapies for progressive MS — a Prog..:

Dangond, Fernando ; Donnelly, Alexis ; Hohlfeld, Reinhard...
Nature Reviews Neurology. 17 (2021) 3 - p. 185-192 , 2021

Link: https://doi.org/10.1038/..

10

Safety of Evobrutinib in Patients With Relapsing Multiple S..:

Montalban, Xavier ; Arnold, Douglas L. ; Weber, Martin S....
Neurology. 96 (2021) 15_supplement - p. , 2021

Link: https://doi.org/10.1212/..

11

Evobrutinib Efficacy is Maintained Over Two Years in an Ope..:

Montalban, Xavier ; Arnold, Douglas L. ; Weber, Martin S....
Neurology. 96 (2021) 15_supplement - p. , 2021

Link: https://doi.org/10.1212/..

12

Pharmacodynamic biomarkers of long-term interferon beta-1a ..:

Freedman, Mark S. ; Wojcik, Jérôme ; Holmberg, Kristina H....
Journal of Neuroimmunology. 360 (2021) - p. 577715 , 2021

Link: https://doi.org/10.1016/..

13

Subgroup analysis of clinical and MRI outcomes in participa..:

Cree, Bruce A.C. ; Bowen, James D. ; Hartung, Hans-Peter...
Multiple Sclerosis and Related Disorders. 49 (2021) - p. 102695 , 2021

Link: https://doi.org/10.1016/..

14

Early MRI outcomes in participants with a first clinical de..:

Freedman, Mark S ; Coyle, Patricia K ; Comi, Giancarlo...
Multiple Sclerosis Journal - Experimental, Translational and Clinical. 7 (2021) 1 - p. 205521732199085 , 2021

Link: https://doi.org/10.1177/..

15

Analysis of frequency and severity of relapses in multiple ..:

De Stefano, Nicola ; Sormani, Maria Pia ; Giovannoni, Gavin...
Multiple Sclerosis Journal. 28 (2021) 1 - p. 111-120 , 2021

Link: https://doi.org/10.1177/..